Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
LAE102 has been shown to both increase lean mass and decrease fat mass in pre-clinical models. If successful, LAE102 could, in combination with a GLP1R agonist, further reduce fat mass and ...
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
The collaboration will accelerate the development of Laekna's experimental drug, LAE102, which belongs to a class of drugs that play a key role in muscle regeneration as well as the breakdown and ...
This development could position LAE102 as a novel option for quality weight control, attracting investor interest in Laekna’s future endeavors. TipRanks is the most comprehensive data set of ...
to accelerate the development of LAE102, a novel ActRIIA mAb as a novel treatment for obesity. Accelerating innovative treatments like this hopefully can make a meaningful impact o Laekna ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback